United Therapeutics CFO James Edgemond Buys 10,000 Shares
CFO James Edgemond purchased 10,000 shares of United Therapeutics at $146.03 each.
Key Points
- James Edgemond, CFO of United Therapeutics, purchased 10,000 shares on June 18, 2026, at an average price of $146.03, totaling $1.46 million.
- United Therapeutics trades on NasdaqGS under the ticker UTHR, with a market cap of approximately $22.78 billion and a P/E ratio of 19.84.
- RBC Capital and Wells Fargo recently maintained 'buy' ratings with price targets of $701 and $738, respectively.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
James Edgemond, the Chief Financial Officer of United Therapeutics Corporation, made a notable purchase of the company's stock. On June 18, 2026, Edgemond bought 10,000 shares at an average price of $146.03 per share. This transaction, which was not part of a pre-planned trading program, totaled around $1.46 million.
Insider Buying and Selling at United Therapeutics Corporation
In addition to James Edgemond's purchase, other insider activities were reported on the same date. Dr. Martine Rothblatt, the Chairperson and CEO, also bought 9,500 shares at the same price of $146.03. Both executives engaged in planned sales on the same date, with Rothblatt selling 9,500 shares at $540.18 and Edgemond selling 10,000 shares at $540.15.
United Therapeutics Corporation Stock Up 4.7%
Shares of NasdaqGS:UTHR traded near $539.81 on Tuesday. United Therapeutics has a market cap of approximately $22.78 billion and a P/E ratio of 19.84. The stock's 52-week range is between $272.12 and $609.35, with a 50-day moving average of $565.40 and a 200-day moving average of $497.47. The company's financial stability is reflected in its current ratio of 4.79 and a quick ratio of 4.12.
$UTHR stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts have recently updated their views on United Therapeutics. On May 7, 2026, RBC Capital maintained its 'buy' rating with a price target of $701, while Wells Fargo upgraded the stock to a 'buy' with a target of $738. The consensus among analysts is a 'buy', with an average price target of $665.23 based on 13 opinions.
About United Therapeutics
United Therapeutics Corporation is a healthcare company based in Silver Spring, Maryland. It focuses on developing and commercializing products for patients with chronic and life-threatening diseases. The company's portfolio includes treatments for pulmonary arterial hypertension and neuroblastoma, among others. Founded in 1996, it is led by Dr. Martine A. Rothblatt and employs approximately 1,400 people.
Bottom Line
The recent insider buying activity by United Therapeutics' CFO James Edgemond is a significant move, reflecting confidence in the company's future. Investors often watch such insider transactions closely, as they can provide insights into management's view of the company's prospects. However, it's important to remember that insider trades are just one piece of the puzzle, and investors should consider the broader financial picture and market conditions.
Get United Therapeutics Corporation alerts
New 13F filings, insider trades, and analyst moves on $UTHR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.